OBJECTIVE: Hyperglycemia is common in the inpatient setting and providers frequently rely on sliding scale insulin. This case study reviews the experience of one hospital moving from high utilization of sliding scale to basal bolus insulin therapy. METHOD: This Retrospective Quality Improvement Study describes the journey of clinicians at a 580-bed hospital to convert from high usage of SSI to BBI. Hyperglycemic adult patients prescribed insulin, with/without a diagnosis of diabetes, were included. RESULTS: Data over the first year showed that patients treated with Glucommander (GM) spent more time in the target range of 70-180 mg/dL than patients treated with non-Glucommander (non-GM), with 2,434 fewer hypoglycemic events and 40,589 fewer hyperglycemic events. Prior to implementation of GM, SSI was close to 95%, BBI at 5%. Within the first month of use, 96% usage of BBI was achieved. Reduction of hypoglycemic events (% of BG < 70 mg/dL) by 21% with 2.16% non-GM compared to GM at 1.74% and severe Hypoglycemia (% of BG < 50 mg/dL) by 50% in the ICU 3% non-GM compared to GM at 1.5%. In addition, patients treated with GM had a shorter LOS than patients treated with non-GM by 3.18 days and used 47.4% less point of care tests per patient. CONCLUSION: Glycemic management improved with use of eGMS. The conversion from SSI to BBI enhanced overall patient safety, eliminated the time and effort otherwise required when manually titrating insulin and reduced overall cost of care for patients on insulin therapy.
OBJECTIVE:Hyperglycemia is common in the inpatient setting and providers frequently rely on sliding scale insulin. This case study reviews the experience of one hospital moving from high utilization of sliding scale to basal bolus insulin therapy. METHOD: This Retrospective Quality Improvement Study describes the journey of clinicians at a 580-bed hospital to convert from high usage of SSI to BBI. Hyperglycemic adultpatients prescribed insulin, with/without a diagnosis of diabetes, were included. RESULTS: Data over the first year showed that patients treated with Glucommander (GM) spent more time in the target range of 70-180 mg/dL than patients treated with non-Glucommander (non-GM), with 2,434 fewer hypoglycemic events and 40,589 fewer hyperglycemic events. Prior to implementation of GM, SSI was close to 95%, BBI at 5%. Within the first month of use, 96% usage of BBI was achieved. Reduction of hypoglycemic events (% of BG < 70 mg/dL) by 21% with 2.16% non-GM compared to GM at 1.74% and severe Hypoglycemia (% of BG < 50 mg/dL) by 50% in the ICU 3% non-GM compared to GM at 1.5%. In addition, patients treated with GM had a shorter LOS than patients treated with non-GM by 3.18 days and used 47.4% less point of care tests per patient. CONCLUSION: Glycemic management improved with use of eGMS. The conversion from SSI to BBI enhanced overall patient safety, eliminated the time and effort otherwise required when manually titrating insulin and reduced overall cost of care for patients on insulin therapy.
Authors: Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez Journal: Endocr Pract Date: 2009 May-Jun Impact factor: 3.443
Authors: Finlay A McAlister; Sumit R Majumdar; Sandra Blitz; Brian H Rowe; Jacques Romney; Thomas J Marrie Journal: Diabetes Care Date: 2005-04 Impact factor: 19.112
Authors: Joseph Aloi; Bruce W Bode; Jagdeesh Ullal; Paul Chidester; Raymie S McFarland; Amy E Bedingfield; Melanie Mabrey; Robby Booth; April Mumpower; Amisha Wallia Journal: J Diabetes Sci Technol Date: 2016-09-25
Authors: J J Pomposelli; J K Baxter; T J Babineau; E A Pomfret; D F Driscoll; R A Forse; B R Bistrian Journal: JPEN J Parenter Enteral Nutr Date: 1998 Mar-Apr Impact factor: 4.016
Authors: Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia Journal: Diabetes Care Date: 2007-05-18 Impact factor: 19.112
Authors: Covadonga Gómez Cuervo; Ana Sánchez Morla; María Asunción Pérez-Jacoiste Asín; Otilia Bisbal Pardo; Luis Pérez Ordoño; Juan Vila Santos Journal: Endocrinol Nutr Date: 2016-01-28
Authors: Guillermo E Umpierrez; Dawn Smiley; Sol Jacobs; Limin Peng; Angel Temponi; Patrick Mulligan; Denise Umpierrez; Christopher Newton; Darin Olson; Monica Rizzo Journal: Diabetes Care Date: 2011-01-12 Impact factor: 19.112
Authors: Guillermo Umpierrez; Saumeth Cardona; Francisco Pasquel; Sol Jacobs; Limin Peng; Michael Unigwe; Christopher A Newton; Dawn Smiley-Byrd; Priyathama Vellanki; Michael Halkos; John D Puskas; Robert A Guyton; Vinod H Thourani Journal: Diabetes Care Date: 2015-07-15 Impact factor: 19.112